1. The Field of the Disclosure
The present disclosure generally relates to tissue closure apparatuses and methods.
2. The Relevant Technology
During intravascular and other related medical procedures, catheters are typically inserted through an incision or puncture in the skin and underlying tissues to access an artery or vein, typically in the groin, neck, or subclavian areas of a patient. The catheter can be inserted through a puncture in the blood vessel and guided to the desired site to perform interventional procedures such as angiography, angioplasty, stent delivery, plaque removal, and infusion of a therapeutic substance.
After the procedure is completed and the catheter is removed from the patient, however, the access hole must be closed to prevent hemorrhage. This is typically achieved by applying pressure over the blood vessel manually and then by applying a pressure bandage or a compressive weight. With conventional methods, the risk of post-puncture hemorrhage is high, which can cause considerable complications. The risk of complications is exacerbated by the concomitant use of anticoagulant medications such as heparin or warfarin and by anti-platelet drugs, which are commonly used following a procedure in order to prevent clot formation and thrombus and/or to treat vascular disease.
It is generally recognized that many currently employed vascular sealing methods and devices and other tissue closure methods and devices incompletely seal holes or wounds in vascular or other tissue. Achieving complete wound closure is particularly important in sealing arterial punctures, which are relatively high pressure systems. For example, under normal blood pressure, the arterial system has a pressure of about 120/80 mmHg or more. Failure to completely close arterial holes can result in hematoma, exsanguination, and in extreme cases, may result in catastrophic consequences, such as limb amputation and death. Moreover, many currently employed vascular devices employ methods and materials that remain on the intravascular endothelial surface or otherwise in the sealed vessel. Materials that remain intravascularly can be a nidus for thrombus or intravascular mural hyperplasia with later spontaneous and catastrophic closure of the vessel.
The present disclosure provides methods and apparatuses that are suitable for closure of vascular punctures or other openings in bodily tissues. The devices and methods described herein are configured for everting a portion of tissue around a puncture site for wound closure on the external surface of the wound. For example, the tissue eversion apparatus may be configured for drawing up a portion of a vessel surrounding a venous or arterial puncture and orienting the inner surface of the vessel at least partially outward so that a closure element may be placed around the everted region on the exterior surface of the vessel. Such a wound closure procedure allows wound healing with little endothelial disruption thereby reducing the chances of intravascular thrombosis or embolism or intimal hyperplasia. In some embodiments, the devices are bioabsorbable.
In one embodiment, a tissue eversion apparatus for everting tissue surrounding a tissue puncture site is disclosed. The tissue eversion apparatus includes an elongate member having a proximal end, a distal end, and an exterior surface. The tissue eversion apparatus further includes a tissue engaging portion disposed on the exterior surface of the elongate member at or near the distal end. The tissue engaging portion is configured to locate and engage a portion or portions of the tissue surrounding the puncture site as the apparatus is withdrawn relative to the puncture.
The tissue engaging portion may include an adhesive portion configured to releasably bond to an edge portion around the tissue puncture to be closed, at least two tissue engaging prongs that extend radially outward in a proximal direction and that are disposed on the exterior surface of the elongate member at or near the distal end, or a combination thereof.
In another embodiment, a system for closing a tissue puncture is described. The system includes a tissue eversion apparatus configured to form an everted tissue region, the tissue eversion apparatus including: an elongate member configured to be positioned in the tissue puncture, the elongate member having a proximal end, a distal end, and an exterior surface, and a tissue engaging portion disposed on the exterior surface of the elongate member at or near the distal end that is configured to locate and engage a portion or portions of the tissue surrounding the puncture site as the apparatus is withdrawn relative to the puncture. The system further includes a closure element configured for capturing at least a portion of the tissue everted by the tissue eversion apparatus so as to close the tissue puncture.
The closure element may include an annular or semi-annular clip configured to be closed around the everted tissue region so as to close the tissue puncture, a generally annular-shaped body disposed about a central axis, the body having an aperture extending therethrough, the body being movable between a first open position configured to receive a portion of the everted tissue in the aperture and a second closed position configured to close around the everted tissue disposed in the aperture so as to close the tissue puncture, and the like.
In yet another embodiment, a method of closing a puncture in a body tissue is described. The method includes (1) positioning a tissue eversion apparatus in the puncture, the tissue eversion apparatus being configured to form an everted tissue region around the puncture. The method further includes (2) withdrawing the tissue eversion apparatus proximally from the opening such that the tissue engaging prongs pierce the tissue and draw the tissue up to form an everted tissue region around the opening in the body tissue, (3) positioning a closure element around at least a portion of the everted tissue region so as to close the opening, and (4) releasing the everted tissue from the tissue engaging prongs.
These and other objects and features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
To further clarify the above and other advantages and features of the present invention, a more particular description of the invention will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. It is appreciated that these drawings depict only illustrated embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
I. Introduction
The present disclosure provides methods and apparatuses that are suitable for closure of vascular punctures or other openings in bodily tissues. The devices and methods described herein are configured for everting a portion of tissue around a puncture site for wound closure on the external surface of the wound. For example, the tissue eversion apparatus may be configured for drawing up (i.e., everting) a portion of a vessel surrounding a venous or arterial puncture and orienting the inner surface of the vessel at least partially outward so that a closure element may be placed around the inverted region on the exterior surface of the vessel.
As used herein, in the specification and appended claims, directional terms, such as “top,” “bottom,” “up,” “down,” “upper,” “lower,” “proximal,” “distal,” and the like are used solely to indicate relative directions in viewing the drawings and are not intended to limit the scope of the claims in any way.
II. Tissue Eversion and Closure Apparatuses
The present disclosure describes tissue eversion apparatuses and methods that can be used to evert a region of tissue around an opening in a body wall, such as a blood vessel. The present disclosure also describes tissue closure systems that include a tissue eversion apparatus and a closure element and a delivery system for delivering a closure element to the everted tissue region. Typically, with the tissue around the opening in an everted state, a closure element can be applied to the everted tissue region so as to close the opening. The apparatuses and methods described herein are configured for wound closure on the external surface of the wound, which allows wound healing with little endothelial disruption thereby reducing the chances of intravascular thrombosis or embolism or intimal hyperplasia. In some embodiments, the devices are bioabsorbable.
Generally, the apparatuses and methods described herein can be used with any type of body tissue that has sufficient strength to be everted by a tissue eversion apparatus and subsequently held together by a tissue closure element described hereinafter. By way of example only, embodiments of the present invention can be used to close openings in tissues that have a wall or membrane function, e.g., pulmonary, intestinal, vascular, urethral, gastric, renal or other wall structures, or in membranes, e.g., amniotic or pericardial membranes. Openings in other types of tissues can also be closed using embodiments of the present invention. Although many types of body tissue can be closed by the methods and apparatuses disclosed herein, the description included herein refers to “vessels” for convenience.
Referring now to the Figures,
In some embodiments, the tissue engaging prongs 106 may include a hinged region (not shown), such as a flattened region or a relieved region to, for example, facilitate proximal folding of the tissue engaging prongs during storage and/or during insertion of the apparatus 100a into a puncture and distal folding of the tissue engaging prongs 106 to facilitate tissue release after a closure element has been applied to the everted tissue region. In one embodiment, the tissue engaging prongs 106 include sharpened ends such that they can pierce at least part way through the tissue to be everted.
In one embodiment, the tissue engaging prongs 106 can be fabricated from a biocompatible material. Suitable examples of biocompatible materials include, but are not limited to stainless steel (e.g., 304V and 316L stainless steels), titanium, nickel titanium alloys (e.g., binary Ni—Ti), or polymeric materials such as polyethylene terephthalate (PET), polyethylene (PE), high-density polyethylene (HDPE), polypropylene (PP), polyetheretherketone (PEEK), and the like. In some embodiments, the tissue engaging prongs 106 can be fabricated from a metal material such as stainless steel, titanium, nickel titanium alloys, or the like and coated with a polymeric material such as polytetrafluoroethylene (PTFE) to improve biocompatibility and reduce friction between the tissue engaging prongs 106 and a patient's tissue as the prongs 106 engage and disengage with the tissue. In some embodiments, the tissue engaging prongs can be formed from a shape-memory material such as a Ni—Ti to facilitate tissue engagement and tissue release. In addition, the use of shape memory materials may be advantageous in cases where the tissue eversion apparatus is to be used more than once.
In one embodiment, the tissue engaging prongs 106 can be fabricated from a wire material, such as a round drawn wire, a drawn wire having a flattened profile, or a ground wire. Alternatively, in some embodiments, the tissue engaging prongs 106 can be fabricated from tubular material similar to materials that are used to fabricate hypodermic needles. In one embodiment, the tissue engaging prongs 106 can have a cross-sectional dimension of about 0.02 mm to about 0.5 mm, about 0.05 mm to about 0.4 mm, about 0.075 mm to about 0.3 mm, about 0.1 mm to about 0.2 mm, or any dimension therebetween. It is noted, however, that the choice of the cross-sectional dimension will be dictated to a certain extent by the mechanical properties of the material used to fabricate the tissue engaging prongs 106 and the intended application of the tissue eversion apparatus 100a.
As will be described in greater detail below in reference to methods of closing a tissue opening, when the tissue engaging prongs 106 engage with the tissue surrounding the tissue opening, the tissue eversion apparatus 100a can be retracted proximally from the wound to pull up (i.e., evert) a portion of tissue surrounding the opening. When the tissue is in an everted state, a closure element, such as a staple or an annular or semi-annular ring, can be applied to the everted tissue region to seal the opening.
In one embodiment, the tissue engaging prongs 106 have a length sufficient to pierce at least part way through the tissue to be everted. One example of a body wall structure is the femoral artery, which is a common access point for a variety of transluminal procedures. The femoral artery has a wall thickness of about 1 mm to about 1.5 mm. In one embodiment, the tissue engaging prongs 106 have a length of at least about 0.25 mm, 0.5 mm, 0.75 mm, 1 mm, 1.25 mm, 1.5 mm, 2 mm, 2.5 mm, or any length therebetween. In another embodiment, the tissue engaging prongs 106 have a length in a range of about 0.25 mm to about 2.5 mm, about 0.5 mm to about 2 mm, about 0.75 mm to about 1.5 mm, or about 1 mm to about 1.5 mm.
Referring now to
Referring now to
The tissue eversion apparatus 100c depicted in
Referring now to
In one embodiment, the adhesive portion 116 may include a methacrylate glue or a similar that can form an adhesive bond with tissue surrounding an opening when the adhesive portion 116 contacts the tissue. In one embodiment, the adhesive portion 116 may include a bioadhesive derived from a marine organism or a microorganism that can form an adhesive bond with tissue surrounding an opening when the bioadhesive contacts the tissue. For example, many marine organisms produce protein-based glues and slimes that are currently being examined for use as temporary and permanent adhesives for medical applications.
Referring now to
In the delivery configuration illustrated in
Referring now to
Referring now to
As will be discussed in greater detail below in reference to methods for closing a tissue puncture, the pierced and everted tissue will slide off of the tissue engagement prongs 206c in the tissue releasing configuration as the tissue eversion apparatus 200b is withdrawn proximally from the tissue puncture. As will also be discussed in greater detail below in reference to methods for closing a tissue puncture, the tissue engagement prongs 206b can be transitioned from the tissue engagement configuration shown in
Referring now to
The closure system 300 includes an elongate member 302 having a proximal end 305, a distal end 303, an exterior surface 301, and at least two tissue engaging prongs 306 disposed on the exterior surface of the elongate member 302. The closure system 300 further includes an outer sheath 304 that, as discussed in detail with respect to
In one embodiment, the elongate member 302 and the tissue engagement prongs 306 are configured to position at least a portion of the everted tissue region within the closure element 308. That is, the elongate member 302 and the tissue engagement prongs 306 are configured to draw up a portion of everted tissue and position it within the body of a closure element 308 such that the closure element 308 can be closed around the everted tissue to close the puncture.
In one embodiment, the closure element 308 may include an annular or semi-annular clip configured to be closed around the everted tissue region so as to close the tissue puncture. For example, the closure element can be a staple or staple-like element that is configured to be clamped around the everted tissue region to close the tissue puncture.
In another embodiment, the closure element 308 may include a generally annular-shaped body disposed about a central axis, such as a crown-shaped structure that is configured to fit over the everted tissue region and close the tissue puncture. The body of the closure element 308 may include an aperture extending through the body such that the elongate member 302 and the tissue engaging prongs 306 can pass a portion of the everted tissue region through the aperture. In one embodiment, the body of the annular-shaped closure element 308 is movable between a first open position configured to receive a portion of the everted tissue in the aperture and a second closed position configured to close around the everted tissue disposed in the aperture so as to close the tissue puncture.
Additional examples of closure elements that can be used to close a tissue puncture include, but are not limited to, suture loops, sutures, cincture elements, rubber band elements, and the like. For example, the everted tissue region can be drawn up into a suture loop such that the suture loop can then be closed around the everted tissue region to close the opening. Likewise, the everted tissue region can be drawn up into an open rubber band element that can then be released so it can close around the everted tissue region and seal the opening.
In one embodiment, the closure element 308 can be fabricated from a biocompatible material. Suitable examples of biocompatible materials include, but are not limited to stainless steel (e.g., 304V and 316L stainless steels), titanium, and nickel titanium alloys (e.g., binary Ni—Ti). In addition, the closure element 308 can be fabricated from a bioabsorbable material. Examples of such materials include polyglycolic acid (PGA) and it co-polymers poly(lactic-co-glycolic acid, poly(glycolide-co-caprolactone), poly(glycolide-co-trimethylene carbonate), Mg alloys, and the like. Other materials are also possible. By being fabricated from a bioabsorbable material, the closure element 308 may dissolve and become absorbed into the body after the opening in the tissue has been closed. Because the closure element 308 may be absorbed into the body, a surgeon in future procedures will not be prevented from reaccessing a similar area of the tissue as is the case with many conventional clips.
In one embodiment, the closure element 308 may include protrusions or tines that help the closure element 308 to grip the tissue and seal the tissue puncture. For example, in the case of the annular body described above, the annular body may include a plurality of tissue engaging protrusions or tines that extend from an outer region of the annular body into the aperture and generally towards a central axis of the annular body. The tissue engaging protrusions or tines can include essentially any structure that is designed to engage the tissue once the tissue has been positioned within aperture. This can include structures designed to puncture or otherwise penetrate the tissue or to structures designed to press against the tissue without penetration therein.
In one embodiment, the tissue engaging protrusions or tines have a length sufficient to pierce at least part way through the everted tissue. One example of a body wall structure that may be punctured and subsequently everted and sealed using the apparatuses and methods described herein is the femoral artery, which is a common access point for a variety of transluminal procedures. The femoral artery has a wall thickness of about 1 mm to about 1.5 mm. In one embodiment, the tissue engaging protrusions or tines that project into the annular body of the closure element have a length of at least about 0.25 mm, 0.5 mm, 0.75 mm, 1 mm, 1.25 mm, 1.5 mm, 2 mm, 2.5 mm, or any length therebetween. In another embodiment, the tissue engaging protrusions or tines have a length in a range of about 0.25 mm to about 2.5 mm, about 0.5 mm to about 2 mm, about 0.75 mm to about 1.5 mm, or about 1 mm to about 1.5 mm. Other types of tissue engaging protrusions or tines may also be used.
III. Methods for Closing a Tissue Puncture
Turning to
Initially, the tissue eversion apparatus 100a is inserted into the body so that the distal end 103 is disposed in the vessel 400, as shown in
As shown in
As the tissue eversion apparatus 100a is further retracted, a closure element 408 can be applied to the everted tissue region 410. As shown in
Sealing the puncture 406 on the external surface of the wound allows wound healing with little endothelial disruption thereby reducing the chances of intravascular thrombosis or embolism or intimal hyperplasia. In addition, if the closure element 408 is bioabsorbable, sealing on the exterior surface of the wound allows the closure element to bioabsorb without danger of the closure element disintegrating and casting off emboli into the circulatory system.
Turning to
As shown in
As shown in
As shown in
Referring now to
Referring now to
Simultaneously or nearly simultaneously with the deployment of the closure element 308, the outer sheath is pushed down distally to assist in folding the tissue engagement prongs 306 distally so as to transition the tissue engagement prongs 306 to a tissue releasing configuration.
Once the tissue engagement prongs 306 have disengaged from the everted tissue region, the tissue closure system 300 can be removed from the body. As the tissue closure system 300 is removed, the closure element 308 can close or can be closed by a clipping device to seal the puncture. If the closure element 308 is made of a bioabsorbable material, the closure element 308 will dissolve and be absorbed into the body after the tissue has grown together over opening 506. This can aid the surgeon in future procedures by allowing the surgeon to reaccess a similar area of the tissue without having to remove or avoid the clip.
While a shape memory, generally annular closure element 308 is shown in
The present disclosure may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the disclosure is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
Number | Name | Date | Kind |
---|---|---|---|
1242139 | Callahan | Oct 1917 | A |
1480935 | Gleason | Jan 1924 | A |
2108206 | Meeker | Feb 1938 | A |
2371978 | Perham | Mar 1945 | A |
2610631 | Calicchio | Sep 1952 | A |
3348595 | Stevens, Jr. | Oct 1967 | A |
3357070 | Sloan | Dec 1967 | A |
3682180 | McFarlane | Aug 1972 | A |
3760810 | Van Hoorn | Sep 1973 | A |
3814104 | Irnich et al. | Jun 1974 | A |
3856018 | Perisse et al. | Dec 1974 | A |
3874388 | King et al. | Apr 1975 | A |
3908662 | Razgulov et al. | Sep 1975 | A |
3926194 | Greenberg et al. | Dec 1975 | A |
3939820 | Grayzel | Feb 1976 | A |
3985138 | Jarvik | Oct 1976 | A |
4011872 | Komiya | Mar 1977 | A |
4018228 | Goosen | Apr 1977 | A |
4018229 | Komiya | Apr 1977 | A |
4189808 | Brown | Feb 1980 | A |
4267995 | McMillan | May 1981 | A |
4501276 | Lombardi | Feb 1985 | A |
4697312 | Freyer | Oct 1987 | A |
4830002 | Semm | May 1989 | A |
5041129 | Hayhurst et al. | Aug 1991 | A |
5059201 | Asnis | Oct 1991 | A |
5100422 | Berguer et al. | Mar 1992 | A |
5133360 | Spears | Jul 1992 | A |
5176691 | Pierce | Jan 1993 | A |
5192287 | Fournier et al. | Mar 1993 | A |
5217471 | Burkhart | Jun 1993 | A |
5237996 | Waldman et al. | Aug 1993 | A |
5254105 | Haaga | Oct 1993 | A |
5290284 | Adair | Mar 1994 | A |
5300078 | Buelna | Apr 1994 | A |
5330445 | Haaga | Jul 1994 | A |
5336231 | Adair | Aug 1994 | A |
5354279 | Hofling | Oct 1994 | A |
5383905 | Golds et al. | Jan 1995 | A |
5403330 | Tuason | Apr 1995 | A |
5403331 | Chesterfield et al. | Apr 1995 | A |
5404621 | Heinke | Apr 1995 | A |
5425740 | Hutchinson, Jr. | Jun 1995 | A |
5462561 | Voda | Oct 1995 | A |
5466241 | Leroy et al. | Nov 1995 | A |
5478353 | Yoon | Dec 1995 | A |
5478354 | Tovey et al. | Dec 1995 | A |
5486186 | Yoon | Jan 1996 | A |
5489288 | Buelna | Feb 1996 | A |
5492119 | Abrams | Feb 1996 | A |
5507744 | Tay et al. | Apr 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5562684 | Kammerer | Oct 1996 | A |
5571120 | Yoon | Nov 1996 | A |
5573540 | Yoon | Nov 1996 | A |
5609597 | Lehrer | Mar 1997 | A |
5613974 | Andreas et al. | Mar 1997 | A |
5613975 | Christy | Mar 1997 | A |
5643318 | Tsukernik et al. | Jul 1997 | A |
5647372 | Tovey et al. | Jul 1997 | A |
5649959 | Hannam et al. | Jul 1997 | A |
5669935 | Rosenman et al. | Sep 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5674231 | Green et al. | Oct 1997 | A |
5693061 | Pierce et al. | Dec 1997 | A |
5713899 | Marnay et al. | Feb 1998 | A |
5728143 | Gough et al. | Mar 1998 | A |
5735736 | Volk | Apr 1998 | A |
5749898 | Schulze et al. | May 1998 | A |
5759189 | Ferragamo et al. | Jun 1998 | A |
5766217 | Christy | Jun 1998 | A |
5782861 | Cragg et al. | Jul 1998 | A |
5792151 | Heck et al. | Aug 1998 | A |
5797928 | Kogasaka | Aug 1998 | A |
5797929 | Andreas et al. | Aug 1998 | A |
5810845 | Yoon | Sep 1998 | A |
5814052 | Nakao et al. | Sep 1998 | A |
5817113 | Gifford, III et al. | Oct 1998 | A |
5845657 | Carberry et al. | Dec 1998 | A |
5855576 | LeVeen et al. | Jan 1999 | A |
5861005 | Kontos | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5873876 | Christy | Feb 1999 | A |
5897487 | Ouchi | Apr 1999 | A |
5906620 | Nakao et al. | May 1999 | A |
5906631 | Imran | May 1999 | A |
5919207 | Taheri | Jul 1999 | A |
5944728 | Bates | Aug 1999 | A |
5957936 | Yoon et al. | Sep 1999 | A |
5957938 | Zhu et al. | Sep 1999 | A |
5964782 | Lafontaine et al. | Oct 1999 | A |
5972009 | Fortier et al. | Oct 1999 | A |
5976161 | Kirsch et al. | Nov 1999 | A |
5984950 | Cragg et al. | Nov 1999 | A |
5993466 | Yoon | Nov 1999 | A |
5993476 | Groiso | Nov 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6022372 | Kontos | Feb 2000 | A |
6024747 | Kontos | Feb 2000 | A |
6056744 | Edwards | May 2000 | A |
6059719 | Yamamoto et al. | May 2000 | A |
6068603 | Suzuki | May 2000 | A |
6083242 | Cook | Jul 2000 | A |
6095155 | Criscuolo | Aug 2000 | A |
6120513 | Bailey et al. | Sep 2000 | A |
6120524 | Taheri | Sep 2000 | A |
6126675 | Shchervinsky et al. | Oct 2000 | A |
6136010 | Modesitt et al. | Oct 2000 | A |
6143004 | Davis et al. | Nov 2000 | A |
6152936 | Christy et al. | Nov 2000 | A |
6161263 | Anderson | Dec 2000 | A |
6165204 | Levinson et al. | Dec 2000 | A |
6178355 | Williams et al. | Jan 2001 | B1 |
6197042 | Ginn et al. | Mar 2001 | B1 |
6221084 | Fleenor | Apr 2001 | B1 |
6248124 | Pedros et al. | Jun 2001 | B1 |
6296657 | Brucker | Oct 2001 | B1 |
6306081 | Ishikawa et al. | Oct 2001 | B1 |
6315782 | Chu et al. | Nov 2001 | B1 |
6322580 | Kanner | Nov 2001 | B1 |
6358258 | Arcia et al. | Mar 2002 | B1 |
6395015 | Borst et al. | May 2002 | B1 |
6397110 | Kuzma | May 2002 | B1 |
6428472 | Haas | Aug 2002 | B1 |
6443963 | Baldwin et al. | Sep 2002 | B1 |
6461366 | Seguin | Oct 2002 | B1 |
6482224 | Michler et al. | Nov 2002 | B1 |
6506209 | Ouchi | Jan 2003 | B2 |
6517498 | Burbank et al. | Feb 2003 | B1 |
6533812 | Swanson et al. | Mar 2003 | B2 |
6547806 | Ding | Apr 2003 | B1 |
6569159 | Edwards et al. | May 2003 | B1 |
6569185 | Ungs | May 2003 | B2 |
6572629 | Kalloo et al. | Jun 2003 | B2 |
6578585 | Stachowski et al. | Jun 2003 | B1 |
6599311 | Biggs et al. | Jul 2003 | B1 |
6610072 | Christy et al. | Aug 2003 | B1 |
6613060 | Adams et al. | Sep 2003 | B2 |
6623509 | Ginn | Sep 2003 | B2 |
6623510 | Carley et al. | Sep 2003 | B2 |
6626918 | Ginn et al. | Sep 2003 | B1 |
6663655 | Ginn et al. | Dec 2003 | B2 |
6676685 | Pedros et al. | Jan 2004 | B2 |
6679904 | Gleeson et al. | Jan 2004 | B2 |
6689051 | Nakada et al. | Feb 2004 | B2 |
6695867 | Ginn et al. | Feb 2004 | B2 |
6736822 | McClellan et al. | May 2004 | B2 |
6743195 | Zucker | Jun 2004 | B2 |
6743259 | Ginn | Jun 2004 | B2 |
6745079 | King | Jun 2004 | B2 |
6746457 | Dana et al. | Jun 2004 | B2 |
6749621 | Pantages et al. | Jun 2004 | B2 |
6749622 | McGuckin, Jr. et al. | Jun 2004 | B2 |
6767356 | Kanner et al. | Jul 2004 | B2 |
6776785 | Yencho et al. | Aug 2004 | B1 |
6837906 | Ginn | Jan 2005 | B2 |
6846319 | Ginn et al. | Jan 2005 | B2 |
6849078 | Durgin et al. | Feb 2005 | B2 |
6890343 | Ginn et al. | May 2005 | B2 |
6896692 | Ginn et al. | May 2005 | B2 |
6904647 | Byers, Jr. | Jun 2005 | B2 |
6942674 | Belef et al. | Sep 2005 | B2 |
6969397 | Ginn | Nov 2005 | B2 |
6984238 | Gifford, III et al. | Jan 2006 | B2 |
7048747 | Arcia et al. | May 2006 | B2 |
7060084 | Loshakove et al. | Jun 2006 | B1 |
7063661 | Okada | Jun 2006 | B2 |
7063711 | Loshakove et al. | Jun 2006 | B1 |
7083635 | Ginn | Aug 2006 | B2 |
7112225 | Ginn | Sep 2006 | B2 |
7122002 | Okada | Oct 2006 | B2 |
7147646 | Dana et al. | Dec 2006 | B2 |
7270672 | Singer | Sep 2007 | B1 |
7316704 | Bagaoisan et al. | Jan 2008 | B2 |
7326230 | Ravikumar | Feb 2008 | B2 |
7331979 | Khosravi et al. | Feb 2008 | B2 |
7335220 | Khosravi et al. | Feb 2008 | B2 |
7338514 | Wahr et al. | Mar 2008 | B2 |
7361183 | Ginn | Apr 2008 | B2 |
7361185 | O'Malley et al. | Apr 2008 | B2 |
7393363 | Ginn | Jul 2008 | B2 |
7396359 | Derowe et al. | Jul 2008 | B1 |
7431727 | Cole et al. | Oct 2008 | B2 |
7507200 | Okada | Mar 2009 | B2 |
7645285 | Cosgrove et al. | Jan 2010 | B2 |
7648493 | Forsberg et al. | Jan 2010 | B2 |
7727249 | Rahmani | Jun 2010 | B2 |
7731655 | Smith et al. | Jun 2010 | B2 |
7749249 | Gelbart et al. | Jul 2010 | B2 |
7799042 | Williamson, IV et al. | Sep 2010 | B2 |
7901428 | Ginn et al. | Mar 2011 | B2 |
8007504 | Zenati et al. | Aug 2011 | B2 |
8048108 | Sibbitt, Jr. et al. | Nov 2011 | B2 |
8226666 | Zarbatany et al. | Jul 2012 | B2 |
8469969 | Kear et al. | Jun 2013 | B2 |
8480687 | Ducharme et al. | Jul 2013 | B2 |
20010046518 | Sawhney | Nov 2001 | A1 |
20010053909 | Nakada | Dec 2001 | A1 |
20020099389 | Michler et al. | Jul 2002 | A1 |
20020106409 | Sawhney et al. | Aug 2002 | A1 |
20020188275 | McGuckin, Jr. | Dec 2002 | A1 |
20030187457 | Weber | Oct 2003 | A1 |
20030233095 | Urbanski et al. | Dec 2003 | A1 |
20040009205 | Sawhney | Jan 2004 | A1 |
20040093027 | Fabisiak et al. | May 2004 | A1 |
20040098044 | Van de Moer et al. | May 2004 | A1 |
20040116943 | Brandt et al. | Jun 2004 | A1 |
20040122349 | Lafontaine et al. | Jun 2004 | A1 |
20040127940 | Ginn et al. | Jul 2004 | A1 |
20040143290 | Brightbill | Jul 2004 | A1 |
20040158127 | Okada | Aug 2004 | A1 |
20040158287 | Cragg et al. | Aug 2004 | A1 |
20040167511 | Buehlmann et al. | Aug 2004 | A1 |
20040191277 | Sawhney et al. | Sep 2004 | A1 |
20040215232 | Belhe et al. | Oct 2004 | A1 |
20040225194 | Smith et al. | Nov 2004 | A1 |
20040236354 | Seguin | Nov 2004 | A1 |
20040267193 | Bagaoisan et al. | Dec 2004 | A1 |
20040267308 | Bagaoisan et al. | Dec 2004 | A1 |
20050010248 | Lafontaine | Jan 2005 | A1 |
20050033359 | Dycus | Feb 2005 | A1 |
20050075665 | Brenzel et al. | Apr 2005 | A1 |
20050085851 | Fiehler et al. | Apr 2005 | A1 |
20050085854 | Ginn | Apr 2005 | A1 |
20050085855 | Forsberg | Apr 2005 | A1 |
20050090859 | Ravlkumar | Apr 2005 | A1 |
20050121042 | Belhe et al. | Jun 2005 | A1 |
20050149065 | Modesitt | Jul 2005 | A1 |
20050149117 | Khosravi et al. | Jul 2005 | A1 |
20050177189 | Ginn et al. | Aug 2005 | A1 |
20050222614 | Ginn et al. | Oct 2005 | A1 |
20050234396 | Forsberg et al. | Oct 2005 | A1 |
20050245876 | Khosravi et al. | Nov 2005 | A1 |
20050256532 | Nayak et al. | Nov 2005 | A1 |
20050261708 | Pasricha et al. | Nov 2005 | A1 |
20050267528 | Ginn et al. | Dec 2005 | A1 |
20050273137 | Ginn | Dec 2005 | A1 |
20060034930 | Khosravi et al. | Feb 2006 | A1 |
20060047313 | Khanna et al. | Mar 2006 | A1 |
20060058844 | White et al. | Mar 2006 | A1 |
20060089635 | Young et al. | Apr 2006 | A1 |
20060095029 | Young et al. | May 2006 | A1 |
20060100664 | Pai et al. | May 2006 | A1 |
20060106420 | Dolan et al. | May 2006 | A1 |
20060253037 | Ginn et al. | Nov 2006 | A1 |
20060253072 | Pai et al. | Nov 2006 | A1 |
20060259049 | Harada et al. | Nov 2006 | A1 |
20070049967 | Sibbitt, Jr. et al. | Mar 2007 | A1 |
20070049968 | Sibbitt et al. | Mar 2007 | A1 |
20070060895 | Sibbitt, Jr. et al. | Mar 2007 | A1 |
20070060950 | Khosravi et al. | Mar 2007 | A1 |
20070060951 | Shannon | Mar 2007 | A1 |
20070083231 | Lee | Apr 2007 | A1 |
20070123817 | Khosravi et al. | May 2007 | A1 |
20070123936 | Goldin et al. | May 2007 | A1 |
20070198058 | Gelbart et al. | Aug 2007 | A1 |
20070203506 | Sibbitt, Jr. et al. | Aug 2007 | A1 |
20070213747 | Monassevitch et al. | Sep 2007 | A1 |
20080004636 | Walberg et al. | Jan 2008 | A1 |
20080009794 | Bagaoisan et al. | Jan 2008 | A1 |
20080045979 | Ma | Feb 2008 | A1 |
20080065151 | Ginn | Mar 2008 | A1 |
20080065152 | Carley | Mar 2008 | A1 |
20080287967 | Andreas et al. | Nov 2008 | A1 |
20080287988 | Smith et al. | Nov 2008 | A1 |
20090088794 | LaFontaine | Apr 2009 | A1 |
20090105728 | Noda et al. | Apr 2009 | A1 |
20090157101 | Reyes et al. | Jun 2009 | A1 |
20090306681 | Del Nido et al. | Dec 2009 | A1 |
20100130965 | Sibbitt, Jr. et al. | May 2010 | A1 |
20100234884 | Lafontaine et al. | Sep 2010 | A1 |
20110066163 | Cho et al. | Mar 2011 | A1 |
20120245603 | Voss | Sep 2012 | A1 |
Number | Date | Country |
---|---|---|
2768324 | Mar 1999 | FR |
2000014634 | Jan 2000 | JP |
2005218868 | Aug 2005 | JP |
WO 9640356 | Dec 1996 | WO |
WO 0056226 | Sep 2000 | WO |
WO 02062234 | Aug 2002 | WO |
WO 03094748 | Nov 2003 | WO |
WO 2005000126 | Jan 2005 | WO |
WO 2005041782 | May 2005 | WO |
WO 2005063129 | Jul 2005 | WO |
WO 2005092204 | Oct 2005 | WO |
WO 2005112782 | Dec 2005 | WO |
WO 2006026116 | Mar 2006 | WO |
WO 2006052611 | May 2006 | WO |
WO 2006052612 | May 2006 | WO |
WO 2006078578 | Jul 2006 | WO |
WO 2006115901 | Nov 2006 | WO |
WO 2006115904 | Nov 2006 | WO |
WO 2006118877 | Nov 2006 | WO |
WO 2007025014 | Mar 2007 | WO |
WO 2007025017 | Mar 2007 | WO |
WO 2007025018 | Mar 2007 | WO |
WO 2007025019 | Mar 2007 | WO |
WO 2007081836 | Jul 2007 | WO |
WO 2010031050 | Mar 2010 | WO |
Entry |
---|
U.S. Appl. No. 60/711,279, filed Aug. 24, 2005, Sibbitt, Jr et al. |
U.S. Appl. No. 60/726,985, filed Oct. 14, 2005, Sibbitt, Jr. et al. |
U.S. Appl. No. 61/097,072, filed Sep. 15, 2008, Sibbitt, Jr. et al. |
U.S. Appl. No. 11/316,775, Apr. 16, 2008, Office Action. |
U.S. Appl. No. 11/316,775, Aug. 6, 2008, Office Action. |
U.S. Appl. No. 11/508,656, Dec. 9, 2009, Restriction Requirement. |
U.S. Appl. No. 11/508,656, Mar. 25, 2010, Office Action. |
U.S. Appl. No. 11/508,656, Aug. 30, 2010, Office Action. |
U.S. Appl. No. 11/508,656, Feb. 10, 2014, Notice of Allowance. |
U.S. Appl. No. 11/508,662, Dec. 28, 2009, Restriction Requirement. |
U.S. Appl. No. 11/508,662, Apr. 14, 2010, Office Action. |
U.S. Appl. No. 11/508,662, Oct. 26, 2010, Office Action. |
U.S. Appl. No. 11/508,715, Jan. 6, 2010, Restriction Requirement. |
U.S. Appl. No. 11/508,715, Apr. 26, 2010, Office Action. |
U.S. Appl. No. 11/508,715, Oct. 18, 2010, Office Action. |
U.S. Appl. No. 12/365,397, Sep. 13, 2010, Restriction Requirement. |
U.S. Appl. No. 12/365,397, Dec. 17, 2010, Office Action. |
U.S. Appl. No. 12/365,397, Jun. 21, 2011, Notice of Allowance. |
U.S. Appl. No. 12/559,377, Dec. 14, 2011, Restriction Requirement. |
U.S. Appl. No. 12/559,377, Feb. 27, 2012, Office Action. |
U.S. Appl. No. 12/559,377, Aug. 3, 2012, Office Action. |
U.S. Appl. No. 13/052,634, Feb. 8, 2013, Restriction Requirement. |
U.S. Appl. No. 13/052,634, Apr. 22, 2013, Office Action. |
U.S. Appl. No. 13/052,634, Nov. 8, 2013, Office Action. |
U.S. Appl. No. 14/532,537, Nov. 4, 2014, Sibbitt Jr. et al. |
U.S. Appl. No. 11/508,662, Mar. 24, 2014, Office Action. |
U.S. Appl. No. 11/508,662, Jul. 25, 2014, Notice of Allowance. |
U.S. Appl. No. 11/508,715, Mar. 27, 2014, Office Action. |
U.S. Appl. No. 11/508,715, Aug. 15, 2014, Office Action. |
U.S. Appl. No. 12/559,377, Jul. 30, 2014, Notice of Allowance. |
U.S. Appl. No. 13/052,634, Dec. 24, 2014, Office Action. |
Number | Date | Country | |
---|---|---|---|
20120296374 A1 | Nov 2012 | US |